Abstract

Calcium Acetate 667-mg Capsules

Author(s): Allen Loyd V Jr

Issue: May/Jun 2013 - Volume 17, Number 3

Page(s): 229

Download in electronic PDF format for $75
  • Calcium Acetate 667-mg Capsules Page 1

Abstract

A formulation for preparing Calcium Acetate 667-mg Capsules. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • calcium acetate
  • capsule formulation
  • hyperphosphatemia
  • drug shortages

Related Categories

  • FORMULATIONS
  • NUTRITION AND NUTRICEUTICALS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2013
Pg. 229
Calcium Acetate 667-mg Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 150-154
Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates)
Author(s): Brandin Thibaut, Wasilewski Maya, Panuccio Camille, Bouguergour Cyrielle, Primas Nicolas, Lamy Edouard, Jean Christophe, Bertault-Peres Pierre, Rathelot Pascal, Curti Christophe, Vanelle Patrice
Nov/Dec 2013
Pg. 501
Cortisone Acetate 25-mg Capsules
Author(s): Allen Loyd V Jr
Sep/Oct 1999
Pg. 415-420
Physical Compatibility of Calcium Acetate and Potassium Phosphates in Parenteral Nutrition Solutions Containing Aminosyn II
Author(s): Zhang Yanping, Xu Quanyun, Trissel Lawrence A, Baker Mary B
Jul/Aug 1999
Pg. 291-294
The Basics of Compounding: Compounding Special Capsules
Author(s): Allen Loyd V Jr
Jul/Aug 2000
Pg. 306-310
Capsule and Tablet Diluents, Featured Excipient:
Author(s): Allen Loyd V Jr
May/Jun 2008
Pg. 276-278
Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration
Author(s): Chan Pak, Heatherly Kathy, Kupiec Thomas C, Trissel Lawrence A
Mar/Apr 2008
Pg. 163-169
Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting
Author(s): de Oliveira Ferreira Anderson, Holandino Carla
Sep/Oct 2001
Pg. 401-405
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release
Author(s): Bogner Robin H, Szwejkowski Jessica, Houston Alana
Sep/Oct 2018
Pg. 433-439
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding
Author(s): Zhao Fang, Dave Vivek S, Mar Mazin Z, Perri Jonathan R
Sep/Oct 2022
Pg. 436-439
Effects of Calcium Polystyrene Sulfonate Formulation Change from Dry Syrup to Oral Solution in Patients with Chronic Kidney Disease
Author(s): Kobayashi Shunsuke, Ogawara Yuka, Imamura Yoshihiko, Kitaoka Akira, Yasu Takeo
Mar/Apr 2021
Pg. 144
Eslicarbazepine Acetate 40-mg/mL in Ora-Plus with Ora-Sweet or Ora-Sweet SF Suspension
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2013
Pg. 230
Estradiol 0.5-mg, 1-mg, or 2-mg Capsules
Author(s): Allen Loyd V Jr
May/Jun 2016
Pg. 209-214
Basics of Compounding: Special Capsules
Author(s): Allen Loyd V Jr
Jan/Feb 2016
Pg. 52
Mupirocin Calcium 2% Cream
Author(s): Allen Loyd V Jr
Jan/Feb 2016
Pg. 53
Resveratrol, Tocopherol Acetate, and Niacinamide Topical Gel-Cream
Author(s): Allen Loyd V Jr
Jan/Feb 2012
Pg. 75
Sodium Acetate 2-mEq/mL and 4-mEq/mL Injections
Author(s): Allen Loyd V Jr
Jan/Feb 2012
Pg. 70
Calcium Chloride 10% Injection
Author(s): Allen Loyd V Jr